Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R. Mato, Colleen Dorsey, Sirin Khajavian et al.|Clinical Cancer Research|2020Cited by 115
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical PracticeLindsey E. Roeker, Anthony R. Mato, Christopher P. Fox et al.|Clinical Cancer Research|2019Cited by 90
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaborationDeborah M. Stephens, John C. Byrd, Kenneth M. Boucher et al.|Haematologica|2020Cited by 36
Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)Jennifer L. Crombie, Marcelo C. Pasquini, Loretta J. Nastoupil et al.|Blood|2023Cited by 17
Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global StudyMatthew S. Davids, Yifan Zhai, Asher Chanan‐Khan et al.|Blood|2022Cited by 16